MannKind Q1 2026 Revenue Rises 15% as Company Prepares for Major FDA Catalysts
MannKind Q1 2026 Revenue Rises 15% as Company Prepares for Major FDA Catalysts
MannKind Corporation reported first-quarter 2026 revenue of about $90 million, up 15% year over year, as the biopharmaceutical company continued shifting from a single-product business into a broader portfolio focused on diabetes, cardiometabolic care, and orphan lung diseases.
The company’s latest earnings call highlighted a mixed but important quarter. Revenue improved from the prior year, yet MannKind posted a GAAP net loss as it increased spending ahead of several possible product launches and clinical milestones.
Key Financial Highlights
For Q1 2026, MannKind reported total revenue of approximately $90.2 million. The company said growth was supported by its expanded product base, including FUROSCIX, Afrezza, royalties, and collaboration-related revenue.
However, the company recorded a GAAP net loss of $16.6 million, or $0.05 per share. On a non-GAAP basis, MannKind reported a loss of $6.9 million, or $0.02 per share. Management said the weaker bottom line reflected higher commercial investment, acquisition-related costs, and preparations for upcoming FDA decisions.
FUROSCIX Adds New Growth Opportunity
FUROSCIX generated $15.5 million in net sales during the quarter. MannKind noted that demand indicators remained positive, with more repeat prescribers and stronger activity in integrated delivery networks.
The company also reaffirmed its 2026 FUROSCIX revenue guidance of $110 million to $120 million. A major upcoming event is the FDA decision for the FUROSCIX ReadyFlow autoinjector, expected on July 26, 2026. If approved, the device could reduce administration time from hours to seconds, potentially making the product easier for patients to use.
Afrezza Pediatric Decision Could Expand Market
MannKind is also preparing for a key FDA decision on Afrezza for pediatric patients, with a PDUFA date of May 29, 2026. If approved, Afrezza could become a needle-free mealtime insulin option for children and adolescents with diabetes.
Afrezza global net sales reached $15.3 million in Q1 2026, up 3% year over year. Management said the company has completed commercial launch preparations for the pediatric indication and believes the product could address an unmet need for families seeking alternatives to mealtime injections.
United Therapeutics Partnership Remains Important
MannKind also discussed its collaboration with United Therapeutics. The company revealed that MNKD-1501 is ralinepag DPI, a dry-powder inhaled therapy being advanced under the partnership.
MannKind received $5 million to support development and may receive up to $35 million in additional development milestones, along with a 10% royalty on net sales. Management said around $15 million of those milestones could be earned over the next 12 months.
Pipeline Focus: Nintedanib DPI and Future Lung Disease Programs
The company also pointed to its inhaled nintedanib DPI program as a major clinical catalyst. MannKind expects a Phase 1b readout in Q3 2026 and plans to begin Phase 2 enrollment. The program targets idiopathic pulmonary fibrosis, a serious lung disease with limited treatment options.
Management said inhaled delivery may help improve tolerability by delivering medicine directly to the lungs. While still in development, the program represents another example of MannKind’s strategy to use its dry-powder technology platform beyond diabetes.
Company Strategy: From One Product to Diversified Portfolio
MannKind described 2026 as a deliberate investment year. The company is spending more now to support future launches, expand its commercial team, and advance its pipeline.
Management said the company has changed significantly since 2022, moving from a business centered mainly on one product into a company with multiple approved products, royalty streams, manufacturing revenue, and development-stage assets.
Outlook
The next few months could be important for MannKind. The company is facing two near-term FDA decision dates, continued FUROSCIX growth efforts, and upcoming data from its nintedanib DPI program.
Although Q1 results showed pressure on earnings, MannKind’s revenue growth and expanding pipeline give investors several milestones to watch. The main question is whether the company can turn these regulatory and commercial opportunities into steady long-term growth.
#MannKind #MNKD #BiotechNews #EarningsReport #SlimScan #GrowthStocks #CANSLIM